Summary:
- This article discusses the development of a new COVID-19 vaccine candidate by Bharat Biotech, an Indian pharmaceutical company.
- The vaccine, called Covaxin, has shown promising results in early clinical trials, with the company reporting that it has been found to be safe and well-tolerated in participants.
- The article also mentions that Covaxin is currently in Phase III clinical trials, which will involve a larger number of participants to further evaluate the vaccine's efficacy and safety.